Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.

Mixed Aspergillosis and Mucormycosis Infections in Patients with COVID-19: Case Series and Literature Review.

Publication date: Jan 17, 2024

Mucormycosis and aspergillosis are angioinvasive infections mainly occurring in immunocompromised patients. However, mixed infection with mucormycosis and aspergillosis in post-COVID-19 patients is rare. In this report, we will report four cases and comprehensively review the published literature on COVID-19 associated mixed infection of aspergillosis and mucormycosis. Besides four of our cases, we searched for published articles using PubMed/MEDLINE, Scopus, and Web of Science databases from the beginning of 2020 until October 2023. During the COVID-19 pandemic, we analyzed 52 cases (4 from our research and 48 from other studies). The most common underlying disease (59. 6%) was diabetes mellitus. However, 19. 2% of COVID-19 patients had no underlying condition. Interestingly, rhino-orbital-cerebral mucormycosis featured prominently in India and Iran, while other countries primarily reported a higher prevalence of pulmonary cases. In conclusion, this study highlights the presence of mixed aspergillosis and mucormycosis in COVID-19 patients who previously had common underlying diseases or even a healthy immune system. Therefore, managing COVID-19 patients should involve screening serum and respiratory samples using biomarkers to detect superinfections.

Concepts Keywords
Diabetes Aspergillosis
Iran Co-infection
Mucormycosis COVID-19
Superinfections Mucormycosis

Semantics

Type Source Name
disease MESH Aspergillosis
disease MESH Mucormycosis
disease MESH Infections
disease MESH COVID-19
disease MESH immunocompromised patients
disease MESH mixed infection
disease VO report
disease MESH diabetes mellitus
pathway REACTOME Immune System
disease MESH superinfections

Original Article

(Visited 1 times, 1 visits today)